Jade Biosciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Jade Biosciences (Nasdaq: JBIO), a biotechnology company developing therapies for autoimmune diseases, has announced its participation in two upcoming investor conferences.

CEO Tom Frohlich and CSO Dr. Andrew King will present at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 p.m. ET, and the 2025 Stifel Biotech Summer Summit on August 13, 2025, at 7:30 a.m. ET. The management team will also host one-on-one investor meetings during both events.

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences.

Jade’s Chief Executive Officer, Tom Frohlich, and Chief Scientific Officer and Head of R&D, Andrew King, BVMS, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, starting at 3:00 p.m. ET. A live webcast will be available on the Investors & Media section of Jade’s website, with an archived replay accessible for 90 days following the event.

Mr. Frohlich and Dr. King will also take part in a fireside chat at the 2025 Stifel Biotech Summer Summit on August 13, 2025, starting at 7:30 a.m. ET.

Members of the Jade management team will host one-on-one investor meetings during the conferences.

About Jade Biosciences, Inc.

Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the expected timelines for JADE101 entering the clinic, the potential of Jade’s product candidates to become best-in-class therapies and their potential therapeutic uses. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.

Jade Biosciences Contact

Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134

FAQ

When is Jade Biosciences (JBIO) presenting at the H.C. Wainwright Kidney Conference?

Jade Biosciences will present at the H.C. Wainwright Kidney Virtual Conference on July 14, 2025 at 3:00 p.m. ET.

Where can I watch Jade Biosciences' (JBIO) conference presentations?

The H.C. Wainwright conference presentation will be available via live webcast on Jade's website in the Investors & Media section, with a replay accessible for 90 days after the event.

When is Jade Biosciences (JBIO) presenting at the Stifel Biotech Summer Summit?

Jade Biosciences will present at the Stifel Biotech Summer Summit on August 13, 2025 at 7:30 a.m. ET.

Who will be presenting at the upcoming Jade Biosciences (JBIO) investor conferences?

CEO Tom Frohlich and CSO Dr. Andrew King will participate in fireside chats at both conferences.